$Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma$

09.28.23

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

by Alex Kadhim

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

09.15.23

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

by Alex Kadhim

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

08.22.23

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

by Alex Kadhim

A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies

08.08.23

A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies

by Alex Kadhim

Teclistamab “Offers Substantial Clinical Benefit over Physician’s Choice of Therapy” in Triple-Class Exposed RRMM

06.26.23

Teclistamab “Offers Substantial Clinical Benefit over Physician’s Choice of Therapy” in Triple-Class Exposed RRMM

by Eleanor Mayfield, ELS

Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

06.09.23

Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

by Eleanor Mayfield, ELS

EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells

05.11.23

EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells

by Eleanor Mayfield, ELS

In Multiple Myeloma, T-Cell Response to TCEs “Is Determined by Pre-Existing Cell State”

05.09.23

In Multiple Myeloma, T-Cell Response to TCEs “Is Determined by Pre-Existing Cell State”

by Eleanor Mayfield, ELS

In MajesTEC-1 Trial, Tocilizumab Reduced Recurrent CRS in Patients Treated with Teclistamab for RRMM

05.04.23

In MajesTEC-1 Trial, Tocilizumab Reduced Recurrent CRS in Patients Treated with Teclistamab for RRMM

by Eleanor Mayfield, ELS

Theme picker